Alessio Amatu

Cytowane przez

	Wszystkie	Od 2018
Cytowania	7660	5918
h-indeks	36	31
i10-indeks	65	58

1400

700

350

1050

2010201120122013201420152016201720182019202020212022202319 31 36 69 152 307 437 585 732 911 1082 1288 1353 544

Dostęp publiczny

Wyświetl wszystko

31 artykułów

3 artykuły

dostępne

niedostępne

Objęte finansowaniem

Współautorzy

Salvatore SienaUniversità degli Studi di Milano, Dipartimento di Oncologia, Ospedale Niguarda, Milano, ItalyZweryfikowany adres z unimi.it
Andrea Sartore-BianchiClinical Molecular Oncology, Niguarda Cancer Center, Milano - ItalyZweryfikowany adres z ospedaleniguarda.it
Alberto BardelliUniversity of Torino - Candiolo Cancer Institute IRCCSZweryfikowany adres z ircc.it
Federica Di NicolantonioUniversity of Torino, Dept of Oncology & Candiolo Cancer Institute, FPO - IRCCSZweryfikowany adres z unito.it
Silvia MarsoniIFOMZweryfikowany adres z ifom.eu
GIULIA SIRAVEGNAInstructor in Medicine, Harvard Medical SchoolZweryfikowany adres z mgh.harvard.edu
Gianluca MauriUniversità degli Studi di MilanoZweryfikowany adres z unimi.it
Andrea CassingenaATS Milano Città MetropolitanaZweryfikowany adres z ats-milano.it
Livio TrusolinoProfessor, University of Torino School of Medicine, ItalyZweryfikowany adres z ircc.it
Angelo VanzulliOspedale Niguarda, University of Milan, ItalyZweryfikowany adres z ospedaleniguarda.it
Filippo PietrantonioZweryfikowany adres z istitutotumori.mi.it
Giovanna MarrapeseNiguarda Cancer Center, Ospedale Niguarda Ca' Granda, Milan, ItalyZweryfikowany adres z ospedaleniguarda.it
Sabrina ArenaIRCC-University of Torino Medical School Laboratory of Molecular Genetics S.P. 142, km 3.95 CandioloZweryfikowany adres z ircc.it
Fortunato CiardielloProfessore di oncologia medica, seconda università di napoliZweryfikowany adres z unina2.it
Laura PalmeriNiguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, ItalyZweryfikowany adres z ospedaleniguarda.it
Giovanni Crisafulli, PhDBioinformatics Manager, Computational Scientist, IFOM, University of Turin,Zweryfikowany adres z ircc.it
Catia MoutinhoAssociate DirectorZweryfikowany adres z garvan.org.au
Manel EstellerDirector, Josep Carreras Leukaemia Research Institute. University of Barcelona and ICREAZweryfikowany adres z carrerasresearch.org
Silvia GhezziOspedale NiguardaZweryfikowany adres z ospedaleniguarda.it
sandra misaleSenior Research Scientist, Memorial Sloan Kettering Cancer CenterZweryfikowany adres z mskcc.org

Obserwuj

Alessio Amatu

Niguarda Cancer Center, Grande Ospedale Metropolitano Niguarda, Milan, Italy

Zweryfikowany adres z ospedaleniguarda.it

cancer - oncology - medical oncology - oncologia - oncologia medica


Tytuł Sortuj wg cytatów Sortuj wg roku Sortuj wg tytułu	Cytowane przez Cytowane przez	Rok
Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients G Siravegna, B Mussolin, M Buscarino, G Corti, A Cassingena, ... Nature medicine 21 (7), 795-801, 2015	1002	2015
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of … A Sartore-Bianchi, L Trusolino, C Martino, K Bencardino, S Lonardi, ... The Lancet Oncology 17 (6), 738-746, 2016	819	2016
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1 … A Drilon, S Siena, SHI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Cancer discovery 7 (4), 400-409, 2017	690	2017
Amplification of the MET Receptor Drives Resistance to Anti-EGFR Therapies in Colorectal Cancer A Bardelli, S Corso, A Bertotti, S Hobor, E Valtorta, G Siravegna, ... Cancer discovery 3 (6), 658-673, 2013	651	2013
NTRK gene fusions as novel targets of cancer therapy across multiple tumour types A Amatu, A Sartore-Bianchi, S Siena ESMO open 1 (2), e000023, 2016	485	2016
Blockade of EGFR and MEK intercepts heterogeneous mechanisms of acquired resistance to anti-EGFR therapies in colorectal cancer S Misale, S Arena, S Lamba, G Siravegna, A Lallo, S Hobor, M Russo, ... Science translational medicine 6 (224), 224ra26-224ra26, 2014	269	2014
Adaptive mutability of colorectal cancers in response to targeted therapies M Russo, G Crisafulli, A Sogari, NM Reilly, S Arena, S Lamba, A Bartolini, ... Science 366 (6472), 1473-1480, 2019	261	2019
ALK, ROS1, and NTRK Rearrangements in Metastatic Colorectal Cancer F Pietrantonio, F Di Nicolantonio, AB Schrock, J Lee, S Tejpar, ... Journal of the National Cancer Institute 109 (12), djx089, 2017	195	2017
BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis C Cremolini, M Di Bartolomeo, A Amatu, C Antoniotti, R Moretto, ... Annals of oncology 26 (10), 2092-2097, 2015	185	2015
Discovery of methylated circulating DNA biomarkers for comprehensive non-invasive monitoring of treatment response in metastatic colorectal cancer L Barault, A Amatu, G Siravegna, A Ponzetti, S Moran, A Cassingena, ... Gut 67 (11), 1995-2005, 2018	180	2018
Tropomyosin receptor kinase (TRK) biology and the role of NTRK gene fusions in cancer A Amatu, A Sartore-Bianchi, K Bencardino, EG Pizzutilo, F Tosi, S Siena Annals of Oncology 30, viii5-viii15, 2019	159	2019
Sensitivity to entrectinib associated with a novel LMNA-NTRK1 gene fusion in metastatic colorectal cancer A Sartore-Bianchi, E Ardini, R Bosotti, A Amatu, E Valtorta, A Somaschini, ... JNCI: Journal of the National Cancer Institute 108 (1), 2016	142	2016
Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: Combined results from two phase I trials (ALKA-372-001 and STARTRK-1) Cancer … A Drilon, S Siena, SI Ou, M Patel, MJ Ahn, J Lee, TM Bauer, AF Farago, ... Published by S. Karger AG, Basel www. karger. com/cro Gupta et al.: A …, 2019	130	2019
Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild‐type KRAS advanced biliary tract cancer: A randomized phase 2 … F Leone, D Marino, S Cereda, R Filippi, C Belli, R Spadi, G Nasti, ... Cancer 122 (4), 574-581, 2016	128	2016
Digital PCR quantification of MGMT methylation refines prediction of clinical benefit from alkylating agents in glioblastoma and metastatic colorectal cancer L Barault, A Amatu, FE Bleeker, C Moutinho, C Falcomatà, V Fiano, ... Annals of oncology 26 (9), 1994-1999, 2015	118	2015
Effect of KRAS and BRAF mutations on survival of metastatic colorectal cancer after liver resection: a systematic review and meta-analysis F Tosi, E Magni, A Amatu, G Mauri, K Bencardino, M Truini, S Veronese, ... Clinical colorectal cancer 16 (3), e153-e163, 2017	109	2017
Radiologic and genomic evolution of individual metastases during HER2 blockade in colorectal cancer G Siravegna, L Lazzari, G Crisafulli, A Sartore-Bianchi, B Mussolin, ... Cancer Cell 34 (1), 148-162. e7, 2018	108	2018
Promoter CpG Island Hypermethylation of the DNA Repair Enzyme MGMT Predicts Clinical Response to Dacarbazine in a Phase II Study for Metastatic Colorectal CancerMGMT as a … A Amatu, A Sartore-Bianchi, C Moutinho, A Belotti, K Bencardino, ... Clinical cancer research 19 (8), 2265-2272, 2013	108	2013
HER2 Positivity Predicts Unresponsiveness to EGFR‐Targeted Treatment in Metastatic Colorectal Cancer A Sartore‐Bianchi, A Amatu, L Porcu, S Ghezzi, S Lonardi, F Leone, ... The oncologist 24 (10), 1395-1402, 2019	88	2019
OEM-TACE: a new therapeutic approach in unresectable intrahepatic cholangiocarcinoma G Poggi, A Amatu, B Montagna, P Quaretti, C Minoia, C Sottani, L Villani, ... Cardiovascular and interventional radiology 32, 1187-1192, 2009	83	2009

Nie można teraz wykonać tej operacji. Spróbuj ponownie później.

Prace 1–20

Cytowania rocznie

Powielone cytowania

Scalone cytowania

Dodaj współautorówWspółautorzy

Obserwuj

Cytowane przez

Współautorzy